Advara HeartCare, the world’s largest single group of cardiologists, has joined forces with Novartis Australia, a leader in innovative medicines, and TerryWhite Chemmart, Australia’s leading community pharmacy network, to form The Heart Health Collective – a partnership that aims to tackle one of the nation’s most pressing health challenges: cardiovascular disease (CVD).
CVD is a leading cause of death and disease burden in Australia, affecting more than 4.2 million Australians and accounting for more than 27% of all deaths annually. The Heart Health Collective is committed to addressing this alarming issue by bringing together their expertise, innovation, and community reach to provide support and resources to those at risk of CVD, ultimately working toward better heart health outcomes for Australians.
Each partner brings unique strengths to the Collective:
• Advara HeartCare is committed to improving Australia’s heart health with an unmatched network of cardiologists and world-class cardiovascular services.
• Novartis Australia, a global pharmaceutical innovator, positions itself as the partner of choice in cardiovascular care, bringing extensive experience and knowledge in developing heart health solutions.
• TerryWhite Chemmart, with its extensive community pharmacy network, provides accessible, pharmacist-led healthcare services that play a vital role in prevention, education, and ongoing care for millions of Australians.
The Heart Health Collective creates a powerful platform to tackle Australia’s cardiovascular disease crisis. The partnership embodies the belief that better heart health outcomes can only be achieved when care, expertise, and innovation come together to work for every Australian.
Through collaborative initiatives, the Collective aims to empower Australians with the knowledge, resources, and treatments they need to take control of their health.
Dr. David O’Donnell, CEO, Advara HeartCare says,
“Improving heart health is at the core of what we do at Advara HeartCare. This collective with TerryWhite Chemmart and Novartis represents an unprecedented opportunity to impact cardiovascular outcomes in Australia.”
Matt Zeller, Country President, Novartis Australia and New Zealand adds,
“Novartis is committed to supporting patients and their families on their journey to better heart health. With our extensive experience in cardiovascular disease (CVD), we are committed to working with a wide variety of partners and stakeholders to bring needed change in tackling CVD in Australia. The Heart Health Collective is a unique and innovative approach to partnering across the patient journey and ecosystem, with a special focus on meeting patients in their local communities. We hope to create new solutions, encourage experimentation, and pioneer novel models of care that will ultimately result in better health outcomes for Australians.”
